{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T14:54:56Z","timestamp":1758293696464,"version":"3.44.0"},"reference-count":44,"publisher":"Endocrinology Research Centre","issue":"4","license":[{"start":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T00:00:00Z","timestamp":1757808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>Cortisol-induced dilated cardiomyopathy (CI-DCM) is a rare manifestation of endogenous hypercortisolism (EH). Optimal management of patients with CI-DCM is a major challenge due to the rarity of the pathology and the lack of expert community guidelines. This article describes a case of successful management of a patient with ACTH-secreting pituitary tumor and CI-DCM.<\/jats:p><jats:p>A 44-year-old patient was hospitalized with symptoms of chronic heart failure (CHF) and EH. The diagnosis of non-ischemic myocardial damage with phenotype of DCM was verified by echocardiography and coronary angiography. According to hormonal and imaging tests, and selective blood sampling from the inferior petrosal sinuses, an ACTH-secreting pituitary adenoma was diagnosed. A transnasal transsphenoidal adenomectomy was planned. Due to the symptoms of CHF and systolo-diastolic dysfunction of the left ventricle (LV), significantly increasing the risk of adverse perioperative cardiac events, the intervention was postponed. Stabilization of the patient\u2019s condition was achieved after 4-month therapy with use of betaAB, ACEI, MRA, diuretics, and steroidogenesis inhibitors. Stabilization of the patient\u2019s condition allowed to perform\u00a0transnasal transsphenoidal adenomectomy without perioperative complications, with postoperative decrease of ACTH and cortisol levels. Follow-up examinations demonstrated preservation of eucorticism, regression of CHF symptoms. progressive decrease of LV size\/volumes with increase of LVEF.<\/jats:p><jats:p>Cortisol hypersecretion can damage myocardium with a phenotype of DCM, with symptoms of CHF being the dominant clinical manifestation of EH. The use of betaAB, ACEI, diuretics, MRA, and steroidogenesis inhibitors is reasonable to control symptoms of CHF and prepare a patient with CI-DCM for surgical intervention. After normalization of cortisol level, regression of CHF symptoms and significant reduction of heart chamber size\/volumes with increase of LVEF are noted, which allows to conclude about reversibility of pathologic cardiac remodeling.<\/jats:p>","DOI":"10.14341\/probl13147","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T13:23:44Z","timestamp":1758201824000},"page":"16-28","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":0,"title":["Dilated cardiomyopathy in a patient with Cushing's disease \u2014 clinical presentation, diagnosis and treatment: a case report"],"prefix":"10.14341","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9008-6893","authenticated-orcid":true,"given":"A. B.","family":"Kuznetsov","sequence":"first","affiliation":[{"name":"I.I. Dedov Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9575-4520","authenticated-orcid":true,"given":"A. Y\u0430.","family":"Grigoryev","sequence":"additional","affiliation":[{"name":"I.I. Dedov Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8385-4113","authenticated-orcid":true,"given":"V. A.","family":"Kuznetsov","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-6441","authenticated-orcid":true,"given":"Zh. E.","family":"Belaya","sequence":"additional","affiliation":[{"name":"I.I. Dedov Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7041-0732","authenticated-orcid":true,"given":"L. Y\u0430.","family":"Rozhinskaya","sequence":"additional","affiliation":[{"name":"I.I. Dedov Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2025,9,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Marchand L, Segrestin B, Lapoirie M, et al. Dilated Cardiomyopathy Revealing Cushing Disease: A Case Report and Literature Review. Medicine (Baltimore). 2015;94(46):e2011. doi: https:\/\/doi.org\/10.1097\/MD.0000000000002011","DOI":"10.1097\/MD.0000000000002011"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Miao S, Lu L, Li L, et al. Clinical Characteristics for the Improvement of Cushing\u2019s Syndrome Complicated With Cardiomyopathy After Treatment With a Literature Review. Front Cardiovasc Med. 2021;8:777964. doi: https:\/\/doi.org\/10.3389\/fcvm.2021.777964","DOI":"10.3389\/fcvm.2021.777964"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Riley DS, Barber MS, Kienle GS, et al. CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol. 2017;89:218-235. doi: https:\/\/doi.org\/10.1016\/j.jclinepi.2017.04.026","DOI":"10.1016\/j.jclinepi.2017.04.026"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14. doi: https:\/\/doi.org\/10.1016\/j.echo.2014.10.003","DOI":"10.1016\/j.echo.2014.10.003"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277-314. doi: https:\/\/doi.org\/10.1016\/j.echo.2016.01.011","DOI":"10.1016\/j.echo.2016.01.011"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"PLOTZ CM, KNOWLTON AI, RAGAN C. The natural history of Cushing\u2019s syndrome. Am J Med. 1952;13(5):597-614. doi: https:\/\/doi.org\/10.1016\/0002-9343(52)90027-2","DOI":"10.1016\/0002-9343(52)90027-2"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Dekkers OM, Horv\u00e1th-Puh\u00f3 E, J\u00f8rgensen JO, et al. Multisystem morbidity and mortality in Cushing\u2019s syndrome: a cohort study. J Clin Endocrinol Metab. 2013;98(6):2277-2284. doi: https:\/\/doi.org\/10.1210\/jc.2012-3582","DOI":"10.1210\/jc.2012-3582"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Albiger N, Testa RM, Almoto B, et al. Patients with Cushing\u2019s syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. Horm Metab Res. 2006;38(6):405-410. doi: https:\/\/doi.org\/10.1055\/s-2006-944545","DOI":"10.1055\/s-2006-944545"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing\u2019s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 2003;88(6):2527-2533. doi: https:\/\/doi.org\/10.1210\/jc.2002-021558","DOI":"10.1210\/jc.2002-021558"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Barahona MJ, Resmini E, Vilad\u00e9s D, et al. Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing\u2019s syndrome. J Clin Endocrinol Metab. 2013;98(3):1093-1099. doi: https:\/\/doi.org\/10.1210\/jc.2012-3547","DOI":"10.1210\/jc.2012-3547"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Neary NM, Booker OJ, Abel BS, et al. Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography. J Clin Endocrinol Metab. 2013;98(5):2045-2052. doi: https:\/\/doi.org\/10.1210\/jc.2012-3754","DOI":"10.1210\/jc.2012-3754"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Hersbach FM, Bravenboer B, Koolen JJ. Hearty hormones. Lancet. 2001;358(9280):468. doi: https:\/\/doi.org\/10.1016\/S0140-6736(01)05626-4","DOI":"10.1016\/S0140-6736(01)05626-4"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Chu JW, Matthias DF, Belanoff J, et al. Successful long-term treatment of refractory Cushing\u2019s disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab. 2001;86(8):3568-3573. doi: https:\/\/doi.org\/10.1210\/jcem.86.8.7740","DOI":"10.1210\/jcem.86.8.7740"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Marazuela M, Aguilar-Torres R, Benedicto A, G\u00f3mez-Pan A. Dilated cardiomyopathy as a presenting feature of Cushing\u2019s syndrome. Int J Cardiol. 2003;88(2-3):331-333. doi: https:\/\/doi.org\/10.1016\/s0167-5273(02)00403-5","DOI":"10.1016\/S0167-5273(02)00403-5"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Petramala L, Battisti P, Lauri G, et al. Cushing\u2019s syndrome patient who exhibited congestive heart failure. J Endocrinol Invest. 2007;30(6):525-528. doi: https:\/\/doi.org\/10.1007\/BF03346339","DOI":"10.1007\/BF03346339"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Ma RC, So WY, Tong PC, et al. Adiposity of the heart revisited: reversal of dilated cardiomyopathy in a patient with Cushing\u2019s syndrome. Int J Cardiol. 2011;151(1):e22-e23. doi: https:\/\/doi.org\/10.1016\/j.ijcard.2010.04.041","DOI":"10.1016\/j.ijcard.2010.04.041"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Yong TY, Li JY. Reversible dilated cardiomyopathy in a patient with Cushing\u2019s syndrome. Congest Heart Fail. 2010;16(2):77-79. doi: https:\/\/doi.org\/10.1111\/j.1751-7133.2009.00123.x","DOI":"10.1111\/j.1751-7133.2009.00123.x"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Al Banna R, Husain A, Al Aali J, et al. Reversible cushing dilated cardiomyopathy mimicking peripartum cardiomyopathy with successful subsequent pregnancy. BMJ Case Rep. 2011;2011:bcr0920114825. doi: https:\/\/doi.org\/10.1136\/bcr.09.2011.4825","DOI":"10.1136\/bcr.09.2011.4825"},{"key":"ref19","unstructured":"J Johnston PC, Atkinson AB, Moore MJ, et al. An unusual cause of reversible cardiomyopathy. Ulster Med J. 2012;81(3):134-135"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Shibusawa N, Yamada M, Hashida T, et al. Dilated cardiomyopathy as a presenting feature of Cushing\u2019s syndrome. Intern Med. 2013;52(10):1067-1071. doi: https:\/\/doi.org\/10.2169\/internalmedicine.52.9051","DOI":"10.2169\/internalmedicine.52.9051"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Kim JH, Kim SY, Park JH. Dilated cardiomyopathy with left ventricular thrombi as a presenting feature of Cushing disease. Can J Cardiol. 2014;30(11):. doi: https:\/\/doi.org\/10.1016\/j.cjca.2014.06.018","DOI":"10.1016\/j.cjca.2014.06.018"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Frustaci A, Letizia C, Verardo R, et al. Atrogin-1 Pathway Activation in Cushing Syndrome Cardiomyopathy. J Am Coll Cardiol. 2016;67(1):116-117. doi: https:\/\/doi.org\/10.1016\/j.jacc.2015.10.040","DOI":"10.1016\/j.jacc.2015.10.040"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Sugihara N, Shimizu M, Kita Y, et al. Cardiac characteristics and postoperative courses in Cushing\u2019s syndrome. Am J Cardiol. 1992;69(17):1475-1480. doi: https:\/\/doi.org\/10.1016\/0002-9149(92)90904-d","DOI":"10.1016\/0002-9149(92)90904-D"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Bal MP, de Vries WB, Steendijk P, et al. Histopathological changes of the heart after neonatal dexamethasone treatment: studies in 4-, 8-, and 50-week-old rats. Pediatr Res. 2009;66(1):74-79. doi: https:\/\/doi.org\/10.1203\/PDR.0b013e3181a283a0","DOI":"10.1203\/PDR.0b013e3181a283a0"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Roy SG, De P, Mukherjee D, et al. Excess of glucocorticoid induces cardiac dysfunction via activating angiotensin II pathway. Cell Physiol Biochem. 2009;24(1-2):1-10. doi: https:\/\/doi.org\/10.1159\/000227803","DOI":"10.1159\/000227803"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"De P, Roy SG, Kar D, Bandyopadhyay A. Excess of glucocorticoid induces myocardial remodeling and alteration of calcium signaling in cardiomyocytes [published correction appears in J Endocrinol. 2011 May;209(2):255]. J Endocrinol. 2011;209(1):105-114. doi: https:\/\/doi.org\/10.1530\/JOE-10-0431","DOI":"10.1530\/JOE-10-0431"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Ren R, Oakley RH, Cruz-Topete D, Cidlowski JA. Dual role for glucocorticoids in cardiomyocyte hypertrophy and apoptosis. Endocrinology. 2012;153(11):5346-5360. doi: https:\/\/doi.org\/10.1210\/en.2012-1563","DOI":"10.1210\/en.2012-1563"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Jin Z, Xia F, Dong J, et al. Omentin-1 attenuates glucocorticoid-induced cardiac injury by phosphorylating GSK3\u03b2. J Mol Endocrinol. 2021;66(4):273-283. doi: https:\/\/doi.org\/10.1530\/JME-20-0236","DOI":"10.1530\/JME-20-0236"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"de Salvi Guimar\u00e3es F, de Moraes WM, Bozi LH, et al. Dexamethasone-induced cardiac deterioration is associated with both calcium handling abnormalities and calcineurin signaling pathway activation. Mol Cell Biochem. 2017;424(1-2):87-98. doi: https:\/\/doi.org\/10.1007\/s11010-016-2846-3","DOI":"10.1007\/s11010-016-2846-3"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Tanaka S, Shibuya H, Suzuki S, et al. Long-term administration of prednisolone: Effects on the myocardial tissue of healthy beagle dogs. J Vet Med Sci. 2021;83(1):84-93. doi: https:\/\/doi.org\/10.1292\/jvms.20-0401","DOI":"10.1292\/jvms.20-0401"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Clark AF, DeMartino GN, Wildenthal K. Effects of glucocorticoid treatment on cardiac protein synthesis and degradation. Am J Physiol. 1986;250(6 Pt 1):C821-C827. doi: https:\/\/doi.org\/10.1152\/ajpcell.1986.250.6.C821","DOI":"10.1152\/ajpcell.1986.250.6.C821"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Czerwinski SM, Kurowski TT, McKee EE, et al. Myosin heavy chain turnover during cardiac mass changes by glucocorticoids. J Appl Physiol (1985). 1991;70(1):300-305. doi: https:\/\/doi.org\/10.1152\/jappl.1991.70.1.300","DOI":"10.1152\/jappl.1991.70.1.300"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Clarke BA, Drujan D, Willis MS, et al. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 2007;6(5):376-385. doi: https:\/\/doi.org\/10.1016\/j.cmet.2007.09.009","DOI":"10.1016\/j.cmet.2007.09.009"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Menconi M, Gonnella P, Petkova V, et al. Dexamethasone and corticosterone induce similar, but not identical, muscle wasting responses in cultured L6 and C2C12 myotubes. J Cell Biochem. 2008;105(2):353-364. doi: https:\/\/doi.org\/10.1002\/jcb.21833","DOI":"10.1002\/jcb.21833"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Nishimura M, Mikura M, Hirasaka K, et al. Effects of dimethyl sulphoxide and dexamethasone on mRNA expression of myogenesis- and muscle proteolytic system-related genes in mouse myoblastic C2C12 cells. J Biochem. 2008;144(6):717-724. doi: https:\/\/doi.org\/10.1093\/jb\/mvn126","DOI":"10.1093\/jb\/mvn126"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Wang L, Luo GJ, Wang JJ, Hasselgren PO. Dexamethasone stimulates proteasome- and calcium-dependent proteolysis in cultured L6 myotubes. Shock. 1998;10(4):298-306. doi: https:\/\/doi.org\/10.1097\/00024382-199810000-00011","DOI":"10.1097\/00024382-199810000-00011"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Wang R, Jiao H, Zhao J, et al. Glucocorticoids Enhance Muscle Proteolysis through a Myostatin-Dependent Pathway at the Early Stage. PLoS One. 2016;11(5):e0156225. doi: https:\/\/doi.org\/10.1371\/journal.pone.0156225","DOI":"10.1371\/journal.pone.0156225"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Wang XJ, Xiao JJ, Liu L, et al. Excessive glucocorticoid-induced muscle MuRF1 overexpression is independent of Akt\/FoXO1 pathway. Biosci Rep. 2017;37(6):BSR20171056. doi: https:\/\/doi.org\/10.1042\/BSR20171056","DOI":"10.1042\/BSR20171056"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Luan G, Li G, Ma X, et al. Dexamethasone-Induced Mitochondrial Dysfunction and Insulin Resistance-Study in 3T3-L1 Adipocytes and Mitochondria Isolated from Mouse Liver. Molecules. 2019;24(10):1982. doi: https:\/\/doi.org\/10.3390\/molecules24101982","DOI":"10.3390\/molecules24101982"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Kokkinopoulou I, Moutsatsou P. Mitochondrial Glucocorticoid Receptors and Their Actions. Int J Mol Sci. 2021;22(11):6054. doi: https:\/\/doi.org\/10.3390\/ijms22116054","DOI":"10.3390\/ijms22116054"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Funder JW. Mineralocorticoid receptor activation and oxidative stress. Hypertension. 2007;50(5):840-841. doi: https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.098012","DOI":"10.1161\/HYPERTENSIONAHA.107.098012"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Oakley RH, Cidlowski JA. Glucocorticoid signaling in the heart: A cardiomyocyte perspective. J Steroid Biochem Mol Biol. 2015;153:27-34. doi: https:\/\/doi.org\/10.1016\/j.jsbmb.2015.03.009","DOI":"10.1016\/j.jsbmb.2015.03.009"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Hung CS (\u555f\u76db) 628401, Chang YY, Tsai CH, et al. Aldosterone suppresses cardiac mitochondria. Transl Res. 2022;239:58-70. doi: https:\/\/doi.org\/10.1016\/j.trsl.2021.08.003","DOI":"10.1016\/j.trsl.2021.08.003"},{"key":"ref44","unstructured":"Omori Y, Mano T, Ohtani T, et al. Glucocorticoids Induce Cardiac Fibrosis via Mineralocorticoid Receptor in Oxidative Stress: Contribution of Elongation Factor Eleven-Nineteen Lysine-Rich Leukemia (ELL). Yonago Acta Med. 2014;57(3):109-116"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13147\/10887","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T13:24:03Z","timestamp":1758201843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,14]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,9,14]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13147","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"type":"electronic","value":"2308-1430"},{"type":"print","value":"0375-9660"}],"subject":[],"published":{"date-parts":[[2025,9,14]]}}}